Literature DB >> 7073946

Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.

V J Richardson, G A Curt, B E Ryman.   

Abstract

Two cell lines, one sensitive and one resistant to the cytotoxic effects of cytosine arabinoside (AraC) were studied in vitro as a drug-resistance model. The sensitivity of these cell lines, to the effects of free and liposomally trapped AraC and AraCTP as well as empty liposomes alone and mixed with free drug, was studied. This was done by following the inhibition of [3H]-dT incorporation into cellular DNA during exposure to the various drugs and liposomes. Some of the liposomal-lipid compositions inhibited [3H]-dT incorporation at very low concentrations, which made them unsuitable for further study. Liposomes composed of a 7:2:1 molar ratio of phosphatidylcholine:cholesterol:phosphatidic acid were selected as a suitable non-inhibitory carrier. Sensitivity of the two cell lines to free AraC differed by 3 logs, when compared in the [3H]-dT-incorporation assay. The resistant cell line was studied further, and was found to be up to 2 logs more sensitive to AraCTP when given in liposomes than to either the free drug alone or mixed with empty liposomes. It appears from these studies that liposomes are able to help overcome drug resistance in this cell line in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073946      PMCID: PMC2010996          DOI: 10.1038/bjc.1982.92

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Cytosine arabinoside uptake by tumour cells in vitro.

Authors:  J H Mulder; K R Harrap
Journal:  Eur J Cancer       Date:  1975-05       Impact factor: 9.162

2.  Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.

Authors:  C N Coleman; D G Johns; B A Chabner
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

3.  Pharmacological effects of phosphatidylserine liposomes.

Authors:  A Bruni; G Toffano; A Leon; E Boarato
Journal:  Nature       Date:  1976-03-25       Impact factor: 49.962

4.  Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells.

Authors:  D Papahadjopoulos; G Poste; W J Vail; J L Biedler
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

5.  Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate.

Authors:  G A Curt; J S Tobias; R A Kramer; A Rosowsky; L M Parker; M H Tattersall
Journal:  Biochem Pharmacol       Date:  1976-09-01       Impact factor: 5.858

6.  Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside.

Authors:  M H Tattersall; K Ganeshaguru; A V Hoffbrand
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

7.  Diffusion of univalent ions across the lamellae of swollen phospholipids.

Authors:  A D Bangham; M M Standish; J C Watkins
Journal:  J Mol Biol       Date:  1965-08       Impact factor: 5.469

8.  Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.

Authors:  T C Chou; D J Hutchinson; F A Schmid; F S Philips
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

9.  A morphologic and biochemical study of the fate of antibody-bearing liposomes.

Authors:  T de Barsy; P Devos; F Van Hoof
Journal:  Lab Invest       Date:  1976-03       Impact factor: 5.662

10.  Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes.

Authors:  L D Steger; R J Desnick
Journal:  Biochim Biophys Acta       Date:  1977-02-04
View more
  5 in total

Review 1.  Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Authors:  Lindsay A M Rein; David A Rizzieri
Journal:  Ther Adv Hematol       Date:  2014-12

Review 2.  Clinical pharmacokinetics of cytarabine formulations.

Authors:  Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Authors:  P A Steerenberg; G Storm; G de Groot; A Claessen; J J Bergers; M A Franken; Q G van Hoesel; K L Wubs; W H de Jong
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Effect of liposomally trapped antitumour drugs on a drug-resistant mouse lymphoma in vivo.

Authors:  V J Richardson; B E Ryman
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.